Cevipabulin

CAS No. 849550-05-6

Cevipabulin( —— )

Catalog No. M32838 CAS No. 849550-05-6

Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 61 In Stock
5MG 51 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cevipabulin
  • Note
    Research use only, not for human use.
  • Brief Description
    Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line).
  • Description
    Cevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line.
  • In Vitro
    Cevipabulin (0-50 nM, 72 hours) shows good activity (between 18 and 40 nM IC50 values) on cell lines from ovarian, breast, prostate, and cervical tumors.Flow cytometry experiments reveal that, Cevipabulin (TTI-237) at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block.Cell Cytotoxicity Assay Cell Line:Human cancer cell lines (SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP, and Hela cells).Concentration:0-50 nM Incubation Time:72 hours Result:The IC50 values are 24±8 nM, 21±4 nM, 18±6 nM, 22±7 nM and 40 nM in SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP and Hela cells.
  • In Vivo
    Cevipabulin (TTI-2370)( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles, in mice) is active by i.v. and p.o. administration against human tumor xenografts, showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg.Animal Model:Athymic nu/nu female mice implanted s.c. in the flank with 1×107 LoVo human colon adenocarcinoma cells Dosage:5, 10, 15, and 20 mg/kg Administration:I.V. injection every 4 days for 4 cycles.Result:The compound showed dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg.Animal Model:Athymic nu/nu female mice implanted s.c. in the flank with 1×106 U87-MG human glioblastoma cells.Dosage:25 mg/kg Administration:P.O. or I.V.Result:The compound was active by p.o. or i.v. administration against human tumor xenografts.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Microtubule Associated
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    849550-05-6
  • Formula Weight
    464.82
  • Molecular Formula
    C18H18ClF5N6O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 16.67 mg/mL (35.86 mM; Ultrasonic )
  • SMILES
    [H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300.?
molnova catalog
related products
  • DS-1040

    DS-1040 (DS1040)?is a small molecule inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50 of 1.7 ng/mL for rabbit TAFIa.

  • Fucoidan

    Fucoidan is found in various species of brown seaweed and algaewith anticancer antiviral neuroprotective immune-modulating.

  • PLH1215

    PLH1215 is an effective AHR inhibitor that can be used to modulate, limit, or suppress the expression of AVIL (advillin). PLH1215 can be employed for the prevention and treatment of cancer.